Computational deep dive surfaces unexplored world of cancer drug targets
Peer-Reviewed Publication
This month, we’re focusing on artificial intelligence (AI), a topic that continues to capture attention everywhere. Here, you’ll find the latest research news, insights, and discoveries shaping how AI is being developed and used across the world.
Updates every hour. Last Updated: 4-May-2026 10:16 ET (4-May-2026 14:16 GMT/UTC)
One person’s side effect could be another person’s treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology.
“Small molecules can have different targets and effects depending on the disease and cell type, and we can use this knowledge to repurpose more drugs to treat more patients,” said lead author Sanju Sinha, PhD, an assistant professor at Sanford Burnham Prebys.Los Angeles, CA – November 14, 2025 - The Terasaki Institute for Biomedical Innovation (TIBI) is pleased to announce its collaboration with the California Institute of Technology (Caltech) on a newly awarded $2.8 million Discovery Stage Research (DISC0) grant from the California Institute for Regenerative Medicine (CIRM).
The University of Oxford’s TIDE Centre today launched the Nature’s Intelligence Studio, a new programme to translate principles observed in biological systems into technologies that support the energy transition and wider sustainability goals, while ensuring fair benefit-sharing with communities in biodiverse regions.
Melanoma is the deadliest form of skin cancer, responsible for thousands of deaths each year; but early detection can dramatically increase survival rates. Now, scientists have developed an advanced artificial intelligence (AI) model that can detect melanoma more accurately by combining skin images with patient metadata. The study achieved 94.5% accuracy, marking a breakthrough in AI-powered early detection of melanoma, thereby advancing smart healthcare systems.